Pharmaceuticals company Cadila Healthcare and its subsidiary Zydus Pharmaceuticals (US) have finalised an agreement with Upsher-Smith Laboratories, a regulatory filing said here on Friday.
This would settle all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules.
"Under the terms of the agreement, Upsher-Smith grants Zydus a licence to market Zydus' generic version of Qudexy XR beginning March 19, 2020, or earlier under certain circumstances," the filing with the BSE said.
However, other terms of the settlement were not disclosed.
--IANS
ag/in/dg
Disclaimer: No Business Standard Journalist was involved in creation of this content